Company profile
Os Therapies Incorporated
Pipeline6 assets
- OST-HER2OST31-164 / HER2 / Bioengineered Listeria monocytogenes (Immunotherapy) / OncologyOsteosarcoma (Pulmonary Metastatic)Phase 2bActiveGlobalBreast CancerPhase 1ActiveGlobalCanine OsteosarcomaApprovedMarketedUS
- OST-AXALAXAL / ADXS-HPV / HPV / Listeria-based Immunotherapy / OncologyHPV-associated cancersPhase 3ActiveGlobal
- OST-503ADXS-503 / KRAS G12 position-related antigens / Listeria-based Immunotherapy / OncologyNon-Small Cell Lung Cancer (NSCLC)Phase 2ActiveGlobalGlioblastoma (GBM)Phase 2ActiveGlobalPancreatic CancerPreclinicalActiveGlobal
- OST-504OST-PSA / ADXS-504 / ADXS31142 / PSA / Listeria-based Immunotherapy / OncologyProstate Cancer (Castration-Resistant)Phase 1bActiveGlobal
- OST-tADCVarious / Tunable Antibody-Drug Conjugate (ADC) / OncologyOvarian CancerPreclinicalActiveGlobalBreast CancerPreclinicalActiveGlobal
- OST-HOT constructsShared hotspot mutations and cancer-testes antigens / Listeria-based Immunotherapy / OncologySolid TumorsPreclinicalActiveGlobal
Latest news23 items
All newsOS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma
Trial Start • Phase 3Trial initiation Wed, Sep 30, 2026
OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma
Trial Results • Phase 2MIB Agents Factor 2026 Osteosarcoma Conference presentation Thu, Jun 25, 2026
OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World
Presentation / Abstract • Phase 2ASCO presentation Thu, May 28, 2026
OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences
Presentation / Abstract • Phase 2ASCO 2026 2.5-Year OS Data Announcement Fri, May 29, 2026, 7:40 AM EDT
OS Therapies Reports First Quarter 2026 Financials and Provides Business Update
Presentation / Abstract • Phase 2ASCO 2026 data release Fri, Jun 5, 2026